Amedisys, Inc. (AMED) Reports Mixed Q3 Results; Cuts FY11 EPS Guidance; Announces Strategic Alignment, Mgmt Changes
Amedisys, Inc. (NASDAQ: AMED) reported Q3 EPS of $0.36, vs. the analyst estimate of $0.50. Revenue for the quarter came in at $374.9 million versus the consensus estimate of $372.06 million.
Also named Ronald Laborde as the company's new President. Dale Redman will transition to the company's CFO. Mike Snow will be leaving from the COO position.
Amedisys, Inc. sees FY2011 EPS of $1.90-$2.00, versus prior guidance of $2.20-$2.40 and the consensus of $2.30.
Also named Ronald Laborde as the company's new President. Dale Redman will transition to the company's CFO. Mike Snow will be leaving from the COO position.
Amedisys, Inc. sees FY2011 EPS of $1.90-$2.00, versus prior guidance of $2.20-$2.40 and the consensus of $2.30.